Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)

Summary

The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.

Timeline

Start

2022-05-25

Primary completion

2024-12-17

Completion

2024-12-17

Outcome

Met primary endpoint

Stopped: “Company decision”

release “positive, primary results up to Day 91 for its Phase II exploratory STARGAZE trial evaluating apraglutide in patients with steroid-refractory gastrointestinal acute Graft-versus-Host Disease” ironwoodpharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apraglutide	Peptide	1.4 mg	Subcutaneous
Subject	Apraglutide	Peptide	3.5 mg	Subcutaneous
Subject	Apraglutide	Peptide	7.6 mg	Subcutaneous

Indications